Institution
Michigan State University
Education•East Lansing, Michigan, United States•
About: Michigan State University is a education organization based out in East Lansing, Michigan, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 60109 authors who have published 137074 publications receiving 5633022 citations. The organization is also known as: MSU & Michigan State.
Topics: Population, Poison control, Gene, Galaxy, Large Hadron Collider
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This article conducted a meta-analysis on the effectiveness of corrective feedback in second language acquisition and found that there was a medium overall effect for corrective feedback and the effect was maintained over time.
Abstract: This study reports on a meta-analysis on the effectiveness of corrective feedback in second language acquisition. By establishing a different set of inclusion/exclusion criteria than previous meta-analyses and performing a series of methodological moves, it is intended to be an update and complement to previous meta-analyses. Altogether 33 primary studies were retrieved, including 22 published studies and 11 Ph.D. dissertations. These studies were coded for 17 substantive and methodological features, 14 of which were identified as independent and moderator variables. It was found that (a) there was a medium overall effect for corrective feedback and the effect was maintained over time, (b) the effect of implicit feedback was better maintained than that of explicit feedback, (c) published studies did not show larger effects than dissertations, (d) lab-based studies showed a larger effect than classroom-based studies, (e) shorter treatments generated a larger effect size than longer treatments, and (f) studies conducted in foreign language contexts produced larger effect sizes than those in second language contexts. Possible explanations for the results were sought through data cross-tabulation and with reference to the theoretical constructs of SLA.
692 citations
••
TL;DR: In this paper, the short-term response of soil denitrification to reduced aeration was studied using the acetylene inhibition method for the assay of denitification, and two distinct phases were observed.
Abstract: The short-term response of soil denitrification to reduced aeration was studied using the acetylene inhibition method for the assay of denitrification. Two distinct phases of denitrification rate were observed. An initial constant rate, termed phase I, was not decreased by chloramphenicol, was increased slightly or not at all by organic carbon amendment, and lasted for 1–3 h. Phase I was attributed to the activity of pre-existing denitrifying enzymes in the soil microflora. Following phase I the denitrification rate increased; chloramphenicol inhibited this increase. In soils without organic-C amendment a second linear phase, termed phase II, was attained after 4–8 h of anaerobic incubation. The linearity of this phase was attributed to the full derepression of denitrifying enzyme synthesis by the indigenous population and to the lack of significant growth of denitrifiers. Phase I rate was dependent on the initial or in situ aeration state of the soil sample; phase II was not. Therefore, phase I may be more directly related to field denitrification rates.
Denitrification rate changes following water saturation of soils in aerobic atmospheres were also examined. Rates were greatly increased by wetting but only after a lag of several hours. Our interpretation is that following wetting of natural soils, anaerobic or partially anaerobic conditions are established by respiration and reduced O2 diffusion rate; this first eliminates O2 inhibition then derepresses the synthesis of denitrifying enzymes. Although denitrifying enzymes are apparently present even in relatively dry soils, their activity is low until O2 inhibition is eliminated. From this evidence we reason that most N is lost from soils during brief periods beginning a few hours after irrigation or a rainfall.
691 citations
••
TL;DR: Hedonic adaptation refers to the process by which individuals return to baseline levels of happiness following a change in life circumstances as mentioned in this paper, and it is a process that is not inevitable.
Abstract: Hedonic adaptation refers to the process by which individuals return to baseline levels of happiness following a change in life circumstances. Dominant models of subjective well-being (SWB) suggest that people can adapt to almost any life event and that happiness levels fluctuate around a biologically determined set point that rarely changes. Recent evidence from large-scale panel studies challenges aspects of this conclusion. Although inborn factors certainly matter and some adaptation does occur, events such as divorce, death of a spouse, unemployment, and disability are associated with lasting changes in SWB. These recent studies also show that there are considerable individual differences in the extent to which people adapt. Thus, happiness levels do change, and adaptation is not inevitable.
691 citations
••
23 May 2007TL;DR: Current requirements engineering (RE) research is reviewed and future research directions suggested by emerging software needs are identified, which aim to address RE needs for emerging systems of the future.
Abstract: In this paper, we review current requirements engineering (RE) research and identify future research directions suggested by emerging software needs. First, we overview the state of the art in RE research. The research is considered with respect to technologies developed to address specific requirements tasks, such as elicitation, modeling, and analysis. Such a review enables us to identify mature areas of research, as well as areas that warrant further investigation. Next, we review several strategies for performing and extending RE research results, to help delineate the scope of future research directions. Finally, we highlight what we consider to be the "hot" current and future research topics, which aim to address RE needs for emerging systems of the future.
690 citations
••
TL;DR: An overview of convalescent plasma is provided, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource.
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., "convalescent") plasma refers to plasma that is collected from individuals following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate immunity to susceptible individuals. There are numerous examples in which convalescent plasma has been used successfully as postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads, and improved survival. Globally, blood centers have robust infrastructure for undertaking collections and constructing inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs. treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, including evidence of benefit, regulatory considerations, logistical work flow, and proposed clinical trials, as scale-up is brought underway to mobilize this critical resource.
689 citations
Authors
Showing all 60636 results
Name | H-index | Papers | Citations |
---|---|---|---|
David Miller | 203 | 2573 | 204840 |
Anil K. Jain | 183 | 1016 | 192151 |
D. M. Strom | 176 | 3167 | 194314 |
Feng Zhang | 172 | 1278 | 181865 |
Derek R. Lovley | 168 | 582 | 95315 |
Donald G. Truhlar | 165 | 1518 | 157965 |
Donald E. Ingber | 164 | 610 | 100682 |
J. E. Brau | 162 | 1949 | 157675 |
Murray F. Brennan | 161 | 925 | 97087 |
Peter B. Reich | 159 | 790 | 110377 |
Wei Li | 158 | 1855 | 124748 |
Timothy C. Beers | 156 | 934 | 102581 |
Claude Bouchard | 153 | 1076 | 115307 |
Mercouri G. Kanatzidis | 152 | 1854 | 113022 |
James J. Collins | 151 | 669 | 89476 |